Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock remains negative
Q1 FY2026 common stock was $0, compared with $0 a year earlier.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Common Stock vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's Mar 2026 common stock of $0 is the lowest of the 11 companies compared; the peer median is $18.5K.
- Common stock amounts to 0.0% of total assets for AARD, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $256.34M | +119.4% | +26.7% | 175.8% |
| Mar 2026 | $291K | +36.0% | +1.0% | 0.1% | |
| Mar 2026 | $63K | +1.6% | +22.8% | 0.1% | |
| Mar 2026 | $25K | +127.3% | — | 0.0% | |
| Mar 2026 | $21K | +31.3% | +44.2% | 0.0% | |
| Mar 2026 | $16K | +100.0% | +58.7% | 0.0% | |
| Mar 2026 | $13K | +0.0% | +2.7% | 0.0% | |
| Mar 2026 | $10K | +11.1% | +14.5% | 0.0% | |
ZURAZura Bio Limited | Mar 2026 | $9K | +28.6% | — | 0.0% |
| Mar 2026 | $6K | +0.0% | +14.5% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding AARD) | $18.5K | +29.9% | +18.6% | 0.0% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.